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Abstract
Background: Severe Clostridium difficile toxin-induced enteritis is characterized by exuberant intestinal tissue
inflammation, epithelial disruption and diarrhea. Adenosine, through its action on the adenosine A2A receptor,
prevents neutrophillic adhesion and oxidative burst and inhibits inflammatory cytokine production. Alanyl-
glutamine enhances intestinal mucosal repair and decreases apoptosis of enterocytes. This study investigates the
protection from enteritis by combination therapy with ATL 370, an adenosine A2A receptor agonist, and alanyl-
glutamine in a rabbit and murine intestinal loop models of C. difficile toxin A-induced epithelial injury.
Methods: Toxin A with or without alanyl-glutamine was administered intraluminally to rabbit ileal or murine cecal
loops. Animals were also given either PBS or ATL 370 parenterally. Ileal tissues were examined for secretion,
histopathology, apoptosis, Cxcl1/KC and IL-10.
Results: ATL 370 decreased ileal secretion and histopathologic changes in loops treated with Toxin A. These effects
were reversed by the A2A receptor antagonist, SCH 58261, in a dose-dependent manner. The combination of ATL 370
and alanyl-glutamine significantly further decreased ileal secretion, mucosal injury and apoptosis more than loops
treated with either drug alone. ATL 370 and alanyl-glutamine also decreased intestinal tissue KC and IL-10.
Conclusions: Combination therapy with an adenosine A2A receptor agonist and alanyl-glutamine is effective in
reversing C. difficile toxin A-induced epithelial injury, inflammation, secretion and apoptosis in animals and has
therapeutic potential for the management of C. difficile infection.
Background
Clostridium difficile is the most common known cause
of nosocomial diarrhea. Recently, the incidence and the
frequency of morbidity and mortality from C. difficile
infection (CDI) have increased [1,2]. These have been
attributed to the BI/NAP1/III/027 strain which is fluoro-
quinolone resistant, carries an 18 bp deletion in the
tcdC gene (a possible negative regulator of toxin gene
production), produces binary toxin and displays hyper-
toxigenic properties [3]. Current treatment consists of
antibiotics that suppress normal flora. While transiently
effective, these treatments result in a 20-30% relapse
rate, prolonged shedding and reacquisition of C. difficile
[4]. Moreover, CDI secondary to the emerging strain
has already been reported to be less responsive to
metronidazole and is associated with more relapses
compared with the historical strains [5]. There are now
more patients requiring colectomies and ICU care. New
non-antimicrobial approaches to treatment are urgently
needed for CDI.
Several clinical studies have shown that glutamine and
its stable derivative, alanyl-glutamine, improve gastroin-
testinal mucosal structure and function following injury
from chemotherapy, radiotherapy or prolonged parent-
eral nutrition [6]. In addition to its role as an important
building block for protein synthesis, glutamine also is a
regulator of intracellular kinases [7], redox status [6],
cell proliferation [8], apoptosis [9] and heat shock
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any medium, provided the original work is properly cited.protein expression [10]. C. difficile toxin A induces acti-
vation of caspases 6, 8, 9 and 3 in intestinal epithelial
cells [11]. Glutamine and alanylglutamine have been
shown to inhibit caspase 8 and decrease toxin A-
induced apoptosis [12]. Activation of adenosine A2A
receptors attenuates inflammation in many tissues. A2A
receptor activation in neutrophils decreases production
of reactive oxygen species. In macrophages A2A receptor
activation decreases secretion of inflammatory cytokines
(e.g. IL-2, IL-12, IL-6, TNFa) and increases IL-10
[13,14]. In mouse ileal tissues, ATL 313, another adeno-
sine A2A receptor agonist, reduced C. difficile toxin A-
induced mucosal injury, neutrophillic infiltration and
cell death [15].
In this study we examined the effect of combining ala-
nyl-glutamine and ATL 370 on secretion and mucosal
structural damage in C. difficile toxin A-induced enteri-
tis in rabbits and cecitis in mice. We also evaluated
apoptosis by immunohistologic staining in the rabbit
ileum and the secretion of inflammatory (keratinocyte-
derived chemokine, KC) and anti-inflammatory (IL-10)
cytokines in the mouse cecum.
Methods
Rabbit ileal loop model
Animal protocols were approved by the University of
Virginia Animal Care and Use Committee. New Zealand
White rabbits weighing approximately 2 kg were fasted
overnight. The rabbits were anesthetized with ketamine
(60-80 mg/kg) and xylazine (5-10 mg/kg), administered
intramuscularly or by inhalational isoflurane. A midline
abdominal incision was made to expose the small bowel.
After the ileum was flushed with 5-10 ml of PBS, 8-10
loops were created by ligation using double ties and a 1-
cm interval was left between the loops. Control loops
were injected with either PBS (1 ml/loop) alone or C.
difficile toxin A (TechLab, Blacksburg VA) (10-20 μg/
loop dissolved in 1 ml of PBS). Treated animals received
alanyl-glutamine (Sigma-Aldrich) at a final concentra-
tion of 3, 10, 30 or 100 mM injected into the intestinal
lumen just prior to toxin A injection. The ligated loops
were then returned to the abdomen and the abdominal
wall sutured closed. Treated animals also received either
the adenosine A2A receptor agonist, ATL 370 (Dogwood
Therapeutics), at 0, 1.5 ng, 15 ng or 150 ng dissolved in
250 uL PBS by intravenous route immediately after
administration of toxin A (time 0) and 2 h after the
addition of toxin A. A separate experiment was per-
formed using equimolar concentrations (3.5 ng, 34.5 ng,
or 345 ng) of adenosine A2A receptor antagonist, SCH
58261 (Tocris Bioscience), given intravenously 5 min
after the administration of ATL 370 (at time 0 and 2 h
later) to investigate the specificity of the agonist effect.
Mouse cecal loop model
To confirm results from the rabbit experiments and
determine the effects of treatment on cytokine produc-
tion, mouse cecal loop experiments were also per-
formed. C57BL/6 male mice, weighing 23-25 g each,
w e r ef a s t e do v e r n i g h t .T h em i c ew e r ea n e s t h e t i z e dw i t h
ketamine (60-80 mg/kg) and xylazine (5-10 mg/kg),
administered intramuscularly. A midline abdominal inci-
sion was made to expose the cecum. After flushing with
PBS, a ligature was placed each at the ileal and colonic
openings of the cecum, while avoiding ligation of the
vascular supply. Control loops were injected with either
PBS (200 μL/loop) alone or C. difficile toxin A (20 μg/
loop dissolved in 200 μL of PBS). Treated animals
received alanyl-glutamine at a final concentration of 100
mM injected into the cecal lumen just prior to toxin A
injection. The ligated cecal loops were then returned to
the abdomen and the abdominal wall sutured closed.
Treated animals also received either the adenosine A2A
receptor agonist, ATL 370, at a dose of 3 ng/g by subcu-
taneous route, immediately after administration of toxin
A (time 0).
Secretion and histopathology
After 4-5 h of incubation, the animals were euthanized
and the abdomen incised. The intestines were exposed
and the lengths of each ligated ileal loop were measured.
Intestinal fluid was extracted from the loop and quanti-
fied. The volume:length ratio (V:L) was calculated in
milliliters per centimeter per loop. The gross description
(clear, serous, purulent, or bloody) of the collected fluid
was also noted. One set of tissues was fixed with 10%
formalin and stained with hematoxylin-eosin for histo-
pathology. Each slide was read blindly by at least 2
investigators (CAW, SWP, GC). A grading scale for his-
topathology of intestinal tissues, previously formulated
and published [16-18], was used to grade each slide
according to mucosal disruption, cellularity, and vascu-
lar congestion. The final histopathologic score is the
mean of the scores of all graders. Samples of intestinal
tissue from control and treated loops were placed in
liquid nitrogen for subsequent protein and RNA
extraction.
In situ apoptotic staining
Paraffin-embedded tissues were analyzed for apoptotic
cells using ApopTag
® Peroxidase In Situ Apoptosis
Detection Kit. All steps were performed according to
the manufacturer’s instructions. Crystal Violet free
Methyl Green was used as the counterstain. Images
were obtained by Olympus BX41TF with Digital Camera
and MIcrosuite Pathology provided by the University of
Virginia Biorepository and Tissue Research Facility.
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cells in 3 randomly chosen high power fields (hpf) per
tissue section quadrant. The total number of cells was
then divided by 12 (3 hpfs × 4 quadrants) and the read-
ing reported as number of apoptotic cells per hpf.
KC, IL-10 enzyme-linked immunosorbent assays (ELISA)
Detection and quantification of KC and IL-10 proteins
present in mouse cecal samples were determined by
using Mouse CXCL1/KC and IL-10 Quantikine ELISA
kits (R&D Systems), respectively. Cecal tissues, harvested
from the mouse cecal loop model described above, were
minced, bead beat for 1 min twice (with 2 min interval
on ice in between bead beating) and lysed in NP-40
lysis buffer for 20 min on ice, followed by spinning at
14,000 rpm at 4
°C for 30 min. Protein concentration in
a 1:10 dilution of the supernatant was measured using
bicinchoninic acid assay (BCA) following the manufac-
turer’s instructions (Pierce Thermo-Fisher Kit) [19].
ELISA on the mouse cecal lysates was performed
according to manufacturer’s instructions [20,21]. Both
sample sets were analyzed in triplicate. Of note, antibo-
dies to rabbit IL-10 and IL-8 are not readily available
and homologous to human sequences by only 80% and
78%, respectively. Thus, we opted to use mouse tissues
to detect cytokine production.
KC and IL-10 gene expression assay
RNA was extracted from mouse cecal tissues using Qia-
gen RNeasy mini Kit according to manufacturer’s
instructions. RNA concentration was quantified and
checked for purity (A260:280 ratio) by standard spectro-
photometry (Biophotometer, Eppendorf, Hamburg, Ger-
many). Synthesis of cDNA by Reverse Transcriptase
PCR was performed using SuperScript III First-Strand
Synthesis System SuperMix (Invitrogen) with the use of
oligo (dT) as primers. cDNA was used in quantitative
PCR for measuring KC and IL-10 expression compared
to hypoxanthine guanine phosphoribosyl (HPRT)
expression. The primers used were: murine HPRT (for-
ward: 5’-TCC CTG GTT AAG CAG TAC AGC CCC-3;
reverse: 5’-CCA ACA AAG TCT GGC CTG TAT CCA
A-3’) (GenBank no. NM_013556.2), IL-10 (forward: 5’-
GGC GCT GTC ATC GAT TTC TCC CC-3’; reverse:
5’-GGC CCT GTA GAC ACC TTG GTC TTGG-3’)
(GenBank no. NM_010548.2) and Cxcl1/KC (forward:
5’-CGC ACG TGT TGA CGC TTC CCT-3’; reverse: 5’-
GTC CCG AGC GAG ACG AGA CCA-3’)( G e n B a n k
no. NM_008176.3). The reaction was performed in a
Bio-Rad iCycler iQ multicolor PCR Detection System
using iCycler software (version 3.0). The relative gene
expression was determined using the 2
-ΔΔCt (Livak)
method using HRPT as the housekeeping gene [22].
Statistical analysis
Continuous variables, such as V:L, histopathologic score,
protein levels, were expressed as means ± standard error
of the mean (SEM). For statistical comparison of the
magnitude of secretion, the amount of inflammation,
and protein levels, a one-way analysis of variance
(ANOVA) with Bonferroni post-hoc test to compare
multiple selected pairs was performed. To compare 2
groups of treatment only, a 2-tailed Student’s unpaired t
test with Welch’s correction was applied.
Results
Adenosine A2A receptor agonist, ATL 370, improved C.
difficile toxin A-induced secretion and epithelial injury in
a dose-dependent manner and these effects were
reversed by the receptor antagonist, SCH 58261
Increasing doses of IV ATL 370 produced decreased
fluid volumes in the rabbit intestinal lumen (Figure 1A).
Histopathology scores did not further improve beyond
ATL 370 15 ng/rabbit IV (Figure 1B). However, increas-
ing doses of SCH 58261 yielded a dose-dependent rever-
sal of the ATL370 effect in both secretion and
histopathology score suggesting adenosine A2A receptor
involvement in these responses (Figure 2). SCH 58261
increased secretion and histopathology score over base-
line, suggesting some activation of A2A receptors by
endogenous adenosine.
ATL 370 and alanyl-glutamine synergistically decreased
toxin A-induced ileal secretion and epithelial injury
As shown in Figure 3A, rabbit intestinal loops chal-
lenged with toxin A displayed a 98% increase in
hemorrhagic secretion (vol/length) compared with
loops treated with PBS only. Toxin A-challenged rab-
bits receiving either a low IV dose of ATL 370 (1.5 ng)
or intraluminal alanyl-glutamine treatment (100 mM)
displayed reduced secretion, each by 27%, however,
this difference did not reach statistical significance.
However, in rabbits treated with both ATL 370 (1.5 ng
IV) and alanyl-glutamine (10-100 mM/loop), further
dose-dependent decreases in secretion were noted. The
V:L decreased by 53%, 67%, 77% and 92% in loops
treated with ATL 370 and alanyl-glutamine at 3, 10, 30
and 100 mM, respectively. As shown in Figure 3B, by
histopathology, toxin A-stimulated intestinal tissues
had significantly elevated histopathology score com-
pared to PBS-stimulated tissues alone. ATL 370 (1.5
ng) and alanyl-glutamine (100 mM) individually
decreased histopathology scores by 21% and 19%,
respectively. Similar to what was observed with secre-
tion, combination treatment resulted to dose-depen-
dent improvement in histopathology (score improved
by 38%, 49%, 51% and 62% in loops treated with ATL
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Figure 1 Effects of ATL 370 alone on C. difficile toxin A-induced secretion and epithelial injury. Increasing doses of intravenous ATL 370
(adenosine A2A receptor agonist; ng) decreased toxin A (10 μg)-induced intraluminal fluid accumulation (A) and histopathology scores (B) in
rabbit ileal loops. Panel 1A: a- P < 0.0001 (one-way ANOVA), and b(PBS vs. Toxin A)- P < 0.001, c(Toxin A vs ATL150)- P < 0.01 (Bonferroni’s).
Panel 1B: a- P < 0.0001 (one-way ANOVA), b(PBS vs. Toxin A) - P < 0.001 (Bonferroni’s), c (Toxin A vs ATL15)- P = 0.04 (Unpaired t-test with
Welch’s). Results were data pooled from 8 to 28 loops from 2 to 5 rabbits per group from 5 separate experiments.
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Figure 2 Effects of SCH-58261 treatment on ATL 370-treated C. difficile toxin A-challenged loops. Increasing doses of adenosine A2A
receptor blocker, SCH 58261 (given IV), reversed the effects of ATL 370 (1.5 ng IV) on secretion (A) and epithelial injury (B) in a dose-dependent
manner in rabbit ileal loops. 3.5 ng of SCH 58261 is equimolar to 1.5 ng of ATL370. Panel 2A: a- P < 0.0001 (one-way ANOVA), and b(PBS vs.
Toxin A)- P < 0.001, c(Toxin A vs ATL + SCH)- P < 0.01 (Bonferroni’s). Panel 2B: a- P < 0.0001 (one-way ANOVA), b(PBS vs. Toxin A)-P< 0.001
(Bonferroni’s). Results were data pooled from 4 to 28 loops from 1 to 6 rabbits per group from 5 separate experiments.
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Figure 3 Effects of low dose ATL 370 and alanyl-glutamine on C. difficile toxin A-induced secretion and epithelial injury. Varying doses
of alanyl-glutamine (AQ; mM) in the lumen when given in addition to intravenous ATL 370 (1.5 ng) showed decrease in toxin A (10 ug)-induced
intraluminal fluid accumulation (A) and epithelial injury (B) in rabbit ileal loops. Panel 3A: a- P = 0.08 (one-way ANOVA), and b (PBS vs. Toxin A)-
P = 0.0002, c (Toxin A vs ATL/AQ10)-P= 0.02, d (Toxin A vs ATL/AQ30)-P= 0.01, e (Toxin A vs ATL/AQ100)-P= 0.0004 (Unpaired t-test with
Welch’s). Panel 3B: a- P < 0.0001 (one-way ANOVA), and b(PBS vs. Toxin A)-P< 0.001, c (Toxin A vs ATL/AQ10)-P< 0.01, d (Toxin A vs ATL/
AQ30)-P< 0.01, e (Toxin A vs ATL/AQ100)-P< 0.001 (Bonferroni’s). Results were data pooled from 4 to 16 loops from 2 rabbits per group from
2 separate experiments.
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Page 6 of 12370 and alanyl-glutamine at 3, 10, 30 and 100 mM,
respectively). Representative images of toxin-challenged
ileal tissues with or without treatment are shown in
Figure 4.
ATL 370 and alanyl-glutamine decreased KC and IL-10 in
toxin A-stimulated mouse cecal tissues
In mouse ligated cecal tissues, KC levels were increased
by 81% in toxin A-treated loops compared with PBS-
E
C D
B A
Figure 4 Effects of ATL 370 and alanyl-glutamine on C. difficile toxin A-induced ileal histopathology. Toxin A (10 μg, B) caused mucosal
disruption, increased cellularity and vascular congestion compared with PBS (A) in rabbit ileal tissues. Treatment with intravenous ATL 370 (1.5
ng, D) or intraluminal alanyl-glutamine (100 mM, C) reduced some epithelial injury. Marked preservation of mucosal architecture was noted in
tissues treated with the combination of ATL and alanyl-glutamine (E)
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Page 7 of 12treated loops (96 ± 6 vs 53 ± 2 μg/mg, p < 0.0001).
Treatment with either AQ or ATL 370 decreased KC in
intoxicated cecal tissues by 73% from the toxin A-trea-
ted loops level (Figure 5A). IL-10 secretion was more
than 2-fold increased in toxin A-treated loops compared
to PBS alone (591 ± 94 vs 228 ± 34 pg/mg tissue, P <
0.01) (Figure 5B). Alanyl-glutamine or ATL 370 alone
did not reduce IL-10 secretion but when combined
together caused a 65% reduction of the cytokine level (p
< 0.01). KC and IL-10 mRNA expressions followed a
similar trend as the ELISAs (Figure 5C and 5D,
respectively).
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Figure 5 Effects of ATL 370 and alanyl-glutamine on cytokine expression. After four hours of incubation, alanyl-glutamine (AQ; 100 mM in
loops) or ATL 370 (3 ng/g s.c.) significantly decreased C. difficile toxin A-induced elevation of KC secretion in mouse cecal tissues (A).
Combination treatment with ATL 370 and AQ significantly decreased KC secretion further. Likewise, IL-10 secretion was increased by toxin A
although not significantly reduced by either AQ or ATL 370 alone (B). Only combination treatment with ATL 370 and alanyl-glutamine
significantly decreased IL-10 secretion (B). C and D show corresponding KC and IL-10 mRNA expressions expressed as fold-change from PBS
control. Number of mice per group: Panels A&B- 5-6; Panels C&D- 3-5. Panel 5A: a- P < 0.0001 (one-way ANOVA), and b (Toxin A vs AQ)-P<
0.01, c (Toxin A vs AQ)-P< 0.001, d (Toxin A vs ATL)-P< 0.01, e (Toxin A vs ATL/AQ)-P< 0.001 (Bonferroni’s). Panel 5B: a- P < 0.0001 (one-way
ANOVA), and b (Toxin A vs PBS)-P< 0.01, c (Toxin A vs ATL/AQ)-P< 0.01 (Bonferroni’s). Panel 5C: a- P = 0.04 (one-way ANOVA), and b (Toxin A
vs ATL/AQ)-P< 0.05 (Bonferroni’s). Panel 5D: a- P = 0.056 (one-way ANOVA)
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Page 8 of 12ATL 370 and alanyl-glutamine decreased toxin A-induced
apoptosis in the intestinal tissues
Toxin A treated rabbit intestinal tissues (Figure 6A)
showed marked apoptotic activity compared with PBS
control tissues (Figure 6B). Due to mucosal sloughing,
most of the apoptotic cells were located in the lumen of
toxin A-treated tissues. Treatment with alanyl-glutamine
( F i g u r e6 C )o rA T L3 7 0( F i g u r e6 D )a l o n er e s u l t e di n
increased mucosal preservation. Apoptotic cells were
noted both in the lumen and within the intact mucosa
and submucosa. Alanyl-glutamine treatment exhibited
better anti-apoptotic activity than ATL 370. Combination
of alanyl-glutamine and ATL 370 resulted in further
decrease in the number of apoptotic cells and increased
preservation of epithelial architecture (Figure 6E).
Discussion
C. difficile toxin A has repeatedly been shown in numer-
ous in vitro and in vivo studies to elicit an exuberant
inflammatory response causing recruitment of inflam-
matory cells (neutrophils, macrophages and mast cells),
secretion of inflammatory cytokines (IL-8, IL1B, TNFa),
cell death, mucosal damage and intestinal secretion
[23-25]. Although both C. difficile toxins A and B gluco-
sylate Rho GTPases [25] and are important in pathogen-
esis during infection [26,27], most animal models of
intoxication–rabbits, mouse, rats and hamsters, are
more responsive to the enterotoxic effects of toxin A
than toxin B [23,28]. This study has shown that adeno-
sine A2A receptor agonist, ATL 370, ameliorates C. diffi-
cile toxin A-induced intestinal epithelial disruption,
inflammation and secretion in the ligated loop model of
enteritis in rabbits. These effects were augmented by co-
administration of the dipeptide, alanyl-glutamine. Signif-
icant decreases in IL-8 and IL-10 in mouse cecal tissues
were also mostly noted with the co-administration of
ATL370 and alanyl-glutamine.
Adenosine is a naturally occurring purine nucleoside
that is produced in many tissues in response to inflam-
matory or hypoxic stimuli. There are 4 known G-protein
coupled adenosine receptors- A1,A 2A,A 2B and A3.A d e -
nosine produces anti-inflammatory activity via A2A
receptors found in immune cells including neutrophils,
macrophages, dendritic cells and platelets. In the pre-
sence of tissue injury or hypoxia, generation of adenosine
is increased and adenosine receptors are upregulated
[29]. Activation of the A2A receptor with adenosine or a
specific A2A receptor agonists inhibits recruitment of
inflammatory cells and expression of inflammatory cyto-
kines [30]. Adenosine inhibits expression of adhesion
molecules (E-selectin and vascular cell adhesion mole-
cule-1, VCAM-1) and secretion of IL-6 and IL-8 in
human endothelial cells [31]. Indeed, it has previously
been reported that intraluminal administration of A2A
agonist, ATL 313, in C. difficile toxin A-challenged mur-
ine ileal loops decreased neutrophil infiltration as mea-
sured by myeloperoxidase activity and tissue TNFa
secretion [15]. C. difficile toxin A-induced intestinal
mucosal injury, intraluminal secretion and apoptosis
were all improved in ileal tissues treated with ATL 313.
Our study using two different animal models (rabbit ileal
and murine cecal loops) and a different adenosine A2A
receptor agonist (ATL 370) corroborated these previous
findings. Interestingly, the high doses of ATL 370 (150
ng) used in this study did not offer additional improve-
ment in histopathologic scores indicating that lower
doses may be sufficient for an optimal effect. The
observed effects of ATL 370 on intestinal secretion were
dose-dependent and reversed by highly specific A2A
antagonist, SCH 58261, also in a dose-dependent manner
suggesting the specificity of the observations to the ade-
nosine A2A receptor. In addition, our study showed that
the anti-inflammatory, anti-secretory and anti-apoptotic
effects from treatment with A2A agonist may be
enhanced by the addition of alanyl-glutamine.
The exact mechanism as to how glutamine and alanyl-
glutamine (a highly soluble and stable derivative of glu-
tamine) protect enterocytes from injury and modulate
inflammatory response is unclear. Alanyl-glutamine is
hydrolyzed to alanine and glutamine in the gut. Gluta-
m i n ei st h em a j o ro x i d a t i v ee n e r g ys o u r c ef o re n t e r o -
cytes, being the building block for purine and
pyrimidine nucleotide synthesis and precursor of glu-
tathione in the gut [32]. Under pathologic or cataboli-
cally stressful conditions, i.e. infection or injury,
glutamine is observed to be depleted and thus, it is con-
sidered as a conditionally essential amino acid [33].
Moreover, glutamine deprivation has been known to
induce apoptosis in intestinal epithelial cells [34]. The
protective effect of glutamine against mucosal injury
and inflammation is thought to be partly mediated by
heat shock proteins [10,35]. More recently, glutamine
has also been considered to be an agonist of peroxisome
proliferator-activated receptor gamma, which belongs to
the family of nuclear receptor proteins which regulates
expression of inflammatory cytokines [36]. It has also
been previously shown that C. difficile toxin A induces
apoptosis by activation of caspases 3, 6, 8, and 9 and
Bid, mitochondrial damage and release of cytochrome c
in T84 cells [11]. Glutamine and alanyl-glutamine inhib-
ited activation of caspase 8 and reduced apoptosis in
T84 cells and improved intestinal secretion and mucosal
disruption in rabbit ileal loops challenged with C. diffi-
cile toxin A [12]. These findings are consistent with
what we have observed where the presence of alanyl-
glutamine enhanced reduction of apoptosis, inflamma-
tion, secretion and epithelial injury in ATL 370-treated,
C. difficile toxin A-stimulated ileal tissues.
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Figure 6 Effects of ATL 370 and alanyl-glutamine on C. difficile toxin A-induced apoptosis. Toxin A (10 μg, B) caused significant apoptosis
in the rabbit ileal tissues compared with PBS (A). Treatment with ATL 370 (1.5 ng/rabbit IV, D) or alanyl-glutamine (AQ;100 mM in loops, C)
caused some reduction of apoptotic cells but only significant difference was noted with treatment with AQ. A marked decrease in apoptotic
cells was noted in tissues treated with the combination of ATL and alanyl-glutamine (E). a- P < 0.0001 (one-way ANOVA), and b (PBS vs. Toxin
A)-P< 0.001, c (Toxin A vs ATL/AQ10)-P< 0.01, d (Toxin A vs ATL/AQ100)-P< 0.001 (Bonferroni’s). Apoptotic cells were counted in 12 high
power fields (3 hpfs/quadrant) per slide from 3 to 4 ileal specimens per group.
Warren et al. BMC Infectious Diseases 2012, 12:13
http://www.biomedcentral.com/1471-2334/12/13
Page 10 of 12The beneficial effect of combination therapy for toxin
A-induced enteritis is less explored in the literature. In
this study we attempted to control both epithelial dis-
ruption and inflammatory response with an adenosine
A2A receptor, ATL 370, and alanyl-glutamine. ATL 370
was delivered parenterally and glutamine intraluminally.
Given the short incubation time (4-5 h) of the experi-
ments, it is conceivable that systemically administered
A2A agonist may have acted mostly on the immune
cells, specifically neutrophils, and endothelial cells,
which are known to express more of the A2A receptors
than on the enterocytes, which express more of A2B
receptors [37-39]. Indeed, other A2A agonists have been
shown to decrease inflammatory responses and
improved survival in mouse models of endotoxemia and
sepsis [40,41]. Several experimental studies have shown
that alanyl-glutamine is at least as effective as glutamine
in improving electrolyte absorption and preserving
mucosal integrity against enterotoxin or chemical insult
[42-46]. Alanyl-glutamine enters enterocytes through
PepT1 proton-coupled peptide transporters and release
L-glutamine by the action of cytosolic peptidases
[47,48]. Although glutamine may affect leukocyte-depen-
dent inflammatory events, such as migration and release
of inflammatory cytokines, in this particular study, glu-
tamine may have caused more of the protective effect
on mucosal architecture and prevention of enterocyte
apoptosis than prevented recruitment of inflammatory
cells. However, release of cytokines from disrupted
epithelial cells contributes to recruitment of immune
cells and inflammatory mediators from the later also
contribute significantly tom u c o s a li n j u r y[ 4 9 ] .T h e s e
joint epithelial and immune responses to a biologic
insult such as an enterotoxin, possibly explains the addi-
tive amelioration of mucosal injury, secretion, and apop-
tosis or even the synergistic effects on the expression of
cytokines with combined treatment in this study.
Whether these observations will hold true in the mouse
model of C. difficile infection remain to be seen but
these preliminary findings raise the potential use of
combination therapy with enteral alanyl-glutamine and
systemic low-dose A2A adenosine agonist in the manage-
ment of C. difficile-induced diarrhea.
Conclusions
In conclusion, activation of A2A adenosine in combina-
tion with alanyl-glutamine reduced toxin-induced intest-
inal secretion, epithelial disruption and inflammation in
the ileal loop model of C. difficile enteritis. A2A adeno-
sine agonists and alanyl-glutamine may have therapeutic
potential for the management of C. difficile infection.
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